Transferrin-dendrimer based gene delivery system

Description:
Reference Number:

Background

Cancer is still a leading cause of death worldwide – accounting for about 13% of all deaths. Molecular chemotherapy - the delivery of toxic genes to tumour cells - can be highly effective in the treatment of cancer, but there is a problem with specificity and selectivity in gene delivery. Hence, there is a real need for effective targeted systems to deliver the cytotoxic DNA specifically to the tumour. Current gene delivery systems provide only low levels of protein expression and, in the case of viruses, have been associated with significant problems. Non-viral delivery systems tend to remain in the lung after intravenous administration, reaching neither the liver nor the intended organ for treatment.

Technology

Researchers at the University of Strathclyde have identified a technique for delivering genes to hard-to-reach tumours without harming healthy tissue. During lab tests the "seek-and-destroy" therapy resulted in 90% of skin cancer tumours disappearing altogether. The team is now investigating the technique's effectiveness at treating different forms of the disease. At present, most gene therapies cannot be delivered to tumours without harming surrounding healthy tissue. The Strathclyde-led team investigated ways of doing so with the use of the plasma protein transferrin, which carries iron through the blood. Carrier proteins for transferrin are often found in large amounts in cancers. During initial tests on skin cancer cells, it was found that the treatment led to a rapid and sustained regression of the tumours over one month, without any apparent signs of toxicity. In 90% of cases, the tumours disappeared altogether.

Key Benefits

  • Delivers therapeutic genes efficiently and selectively to tumours
  • Leaves healthy cells unaffected
  • Fewer side-effects than traditional chemotherapy

Markets and Applications

  • Cancer Treatment

Licensing and Development

This technology is protected by a patent application filed by the University of Strathclyde. Contact is welcomed from organisations interested in developing, licensing or exploiting this technology.

For further information, please contact Research & Knowledge Exchange Services:
e: rkes@strath.ac.uk t: 0141 548 3707 f: 0141 552 4409

Patent Information:
Category(s):
Drug Delivery
For Information Contact: rkes@strath.ac.uk
University of Strathclyde
Inventors:
Christine Dufes
Keywords:
© 2026. All Rights Reserved. Powered by Inteum